# Russell Beckerman

> Russell Beckerman is a biotech entrepreneur and Co-Founder & CEO of Overture Therapeutics, a Cambridge-based company engineering precision antibody medicines targeting obesity and metabolic dysfunction. He previously co-founded 82VS, a venture studio embedded within Alloy Therapeutics that has launched nine drug companies since 2020. His work sits at the intersection of cutting-edge antibody biology, company creation, and the conviction that the next generation of obesity drugs will be antibodies - not peptides.

- **Role:** Co-Founder & CEO at Overture Therapeutics
- **Organizations:** Overture Therapeutics, Alloy Therapeutics, Inc., 82VS
- **From:** Mendham, New Jersey, United States
- **Nationality:** American
- **Education:** High School Diploma, The Pingry School, Bachelor of Arts, Dartmouth College, Bachelor of Engineering in Biotechnology/Biochemical Engineering, Thayer School of Engineering at Dartmouth, MBA (2+2 Program), Harvard Business School
- **Known for:** Co-founded 82VS venture studio within Alloy Therapeutics, which launched 9 drug companies since 2020, Part of the team that grew Alloy Therapeutics to a $1 billion valuation through Series E funding, Founded Overture Therapeutics to develop precision antibody medicines targeting obesity and metabolic dysfunction

## Career timeline

- **2013-2015** — Participated in Waksman Student Scholars Program at Rutgers University, co-publishing 5 DNA sequences from Duckweed genome research for biofuel and bioremediation applications
- **2015-2020** — Attended Dartmouth College and Thayer School of Engineering; worked as undergraduate researcher in Baker Lab Group and Zhang Research Group; served as ski patroller and Safety Officer for DOC First-Year Trips
- **2020-2022** — Joined Catalent Pharma Solutions as a GOLD Associate in process development
- **2021-2022** — Completed Harvard Business School MBA through the 2+2 program
- **2022** — Joined Alloy Therapeutics as Associate Director, Strategy and Corporate Development, Office of the CEO
- **2022-2024** — Co-founded 82VS, a venture studio embedded within Alloy Therapeutics; served as CEO, helping launch 9 drug companies leveraging Alloy's biologics platforms
- **2024** — Co-founded Overture Therapeutics, a Cambridge biotech targeting obesity with precision antibody medicines; backed by Harvard Innovation Launch Lab and Mission BioCapital
- **2026-04** — Alloy Therapeutics announces $40M Series E at $1B valuation, bringing total funding to $222M; Overture Therapeutics continues development of antibody-based obesity therapeutics

## Achievements

- Co-founded 82VS venture studio within Alloy Therapeutics, which launched 9 drug companies since 2020
- Part of the team that grew Alloy Therapeutics to a $1 billion valuation through Series E funding
- Founded Overture Therapeutics to develop precision antibody medicines targeting obesity and metabolic dysfunction
- Backed by Mission BioCapital and Harvard Innovation Launch Lab for Overture Therapeutics
- As a student, co-published 5 DNA sequences from Duckweed genome research at Rutgers
- Completed dual bachelor's degrees plus Harvard MBA before age 28

## Latest updates

- **2026-04** — Alloy Therapeutics closes $40M Series E at $1B valuation with backing from 8VC, Founders Fund, Thiel Capital, Mubadala Capital and others, bringing total funding to $222M
- **2024-00** — Co-founded Overture Therapeutics, focused on precision antibody medicines for obesity; backed by Harvard Innovation Launch Lab and Mission BioCapital

## Links

- Website: https://overture-tx.com
- LinkedIn: https://www.linkedin.com/in/russellbeckerman/

---

Profile page: https://yespress.io/russell-beckerman
Published by YesPress — https://yespress.io
Last updated: 2026-06-06